Overview A Study of JNJ-75220795 in Japanese Participants Status: Not yet recruiting Trial end date: 2022-11-28 Target enrollment: Participant gender: Summary The purpose of this study is to assess the safety and tolerability of single subcutaneous (SC) dose of JNJ-75220795 in Japanese participants. Phase: Phase 1 Details Lead Sponsor: Janssen Pharmaceutical K.K.